Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations

The use of dabrafenib plus trametinib in pediatric low-grade glioma with BRAF V600 mutations led to longer progression-free survival and fewer grade 3 adverse events than standard chemotherapy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-09, Vol.389 (12), p.1108-1120
Hauptverfasser:	Bouffet, Eric, Hansford, Jordan R., Garrè, Maria Luisa, Hara, Junichi, Plant-Fox, Ashley, Aerts, Isabelle, Locatelli, Franco, van der Lugt, Jasper, Papusha, Ludmila, Sahm, Felix, Tabori, Uri, Cohen, Kenneth J., Packer, Roger J., Witt, Olaf, Sandalic, Larissa, Bento Pereira da Silva, Ana, Russo, Mark, Hargrave, Darren R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Brain cancer Brain Tumor Carboplatin Chemotherapy Childhood Cancer Childhood Diseases Clinical outcomes Clinical trials Confidence intervals Glioma Hematology Inhibitor drugs Kinases Mutation Neurology Neurosurgery Oncology Patients Pediatrics Pediatrics General Survival Targeted cancer therapy Treatments in Oncology Tumors Vincristine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The use of dabrafenib plus trametinib in pediatric low-grade glioma with BRAF V600 mutations led to longer progression-free survival and fewer grade 3 adverse events than standard chemotherapy.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2303815